Search

The endocannabinoid system consists of endocannabinoids, cannabinoid receptors and enzymes that synthesise and degrade the endocannabinoids. The cannabinoid receptors (CBR) are an important class of receptors participating in various physiological processes. Many of their effects are mediated by two G protein-coupled receptors (GPCRs), (CB1) and (CB2), although additional receptors may be involved. The purpose of this paper is to present a computer modelling of the CBR and several known cannabinoid ligands aiming to determine the structure-activity relationship by using molecular docking with GOLD software. Four scoring functions provided by GOLD are used for molecular docking of the models of CBR1, its crystal structure and the known cannabinoid ligands. Significant correlations between the biological activity of the ligands and the ChemScore optimization function are established. The results obtained could be further used for in silico experiments of the interaction between CBR and cannabinoid ligands.

Although today among oncology patients use of various preparations of complementary and alternative medicine is more and more frequent, there is unequivocal scientifi c base for their use. Among the often used preparations, especially in the treatment of cancer pain, is cannabis and its derivatives. Cannabinoids act on the endogenous cannabinoid system, with widespread receptors in the central nervous system and peripheral tissues. Although the pharmacology of the cannabinoids is still largely unknown, numerous of their eff ects were investigated. In oncology, studies have been conducted on the effect of cannabinoids on nausea and vomiting during the oncological treatment, the cancer pain and neuropathy, on appetite and weight loss, and the impact on mood, depression and anxiety. It is also observed that some of the cannabinoids have antitumor, but also protumorous activity. There have been many diff erent side eff ects of cannabinoids detected, and in a smaller percentage also the development of addiction. Best known preparations nowadays are dronabinol, nabilon and nabiximol. At the moment, the evidence lack strenght, and large randomized clinical trials are required, which would confi rm predominatly positive results of the research.

This review is an overview of the recent advances in cannabinoid chemistry with a special emphasis on the patent literature. The term cannabinoid includes analogues of the natural components of cannabis, endocannabinoids and a wide array of chemical structures such as 1,5-diarylpyrazoles, indoles, quinolines and arylsulphonamide derivatives capable of acting as cannabinoid receptor agonists and antagonists. These receptors, discovered in the early nineties, seem to be involved in different biochemical processes and thus represent interesting therapeutic targets for drug research